Compare ARDX & WLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | WLYB |
|---|---|---|
| Founded | 2007 | 1807 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Books |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | WLYB |
|---|---|---|
| Price | $5.69 | $36.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $15.14 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 455.0 |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.84% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $38.22 | $0.02 |
| Revenue Next Year | $33.85 | $2.32 |
| P/E Ratio | ★ N/A | $15.27 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.50 | $29.16 |
| 52 Week High | $8.40 | $45.16 |
| Indicator | ARDX | WLYB |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 67.78 |
| Support Level | $5.49 | $36.20 |
| Resistance Level | $6.23 | $38.63 |
| Average True Range (ATR) | 0.31 | 0.53 |
| MACD | -0.06 | 0.82 |
| Stochastic Oscillator | 11.79 | 94.16 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.